Clinical Trials Logo

Congenital Bleeding Disorder clinical trials

View clinical trials related to Congenital Bleeding Disorder.

Filter by:

NCT ID: NCT01312636 Completed - Clinical trials for Congenital Bleeding Disorder

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Start date: March 2011
Phase: N/A
Study type: Observational

This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.

NCT ID: NCT01288391 Completed - Clinical trials for Congenital Bleeding Disorder

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe and Japan. The aim of this trial is to assess the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of single doses of NNC128-0000-2011, when administered i.v. (intravenously) to haemophilia patients.

NCT ID: NCT01272206 Completed - Clinical trials for Congenital Bleeding Disorder

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to investigate the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of NNC 0128-0000-2011 compared to NNC 0128-0000-2021 when given for the first time to healthy human subjects.

NCT ID: NCT01253811 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

mentor™5
Start date: January 2011
Phase: Phase 3
Study type: Interventional

This trial will be conducted in Asia, Europe and the United States of America (USA). The aim of this clinical trial is to investigate long-term safety of rFXIII when administered for prevention of bleeding episodes in children aged between 1 and 6 years with congenital FXIII A-subunit deficiency. This trial is an extension to trial F13CD-3760 (mentor™4, NCT01230021). If applicable the trial will be extended up to maximum 3 years dependent on when recombinant factor XIII will be commercially available in subject's respective country for use in children of 1-6 years of age

NCT ID: NCT01238367 Completed - Clinical trials for Congenital Bleeding Disorder

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Start date: November 2010
Phase: Phase 1
Study type: Interventional

This trial is conducted in Japan. The aim of this clinical trial is to investigate the pharmacokinetics (the effect of the investigated drug on the body) and safety of turoctocog alfa (recombinant factor VIII (N8)) in Japanese subjects with haemophilia A.

NCT ID: NCT01234545 Completed - Clinical trials for Congenital Bleeding Disorder

Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors

Start date: October 2010
Phase: N/A
Study type: Observational

This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII) in patients with haemophilia A and B patients with inhibitors.

NCT ID: NCT01230021 Completed - Clinical trials for Congenital Bleeding Disorder

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

mentor™4
Start date: November 2010
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe and United States of America (USA). The aim of this clinical trial is to investigate the pharmacokinetics (at which rate the substance is distributed and eliminated from the body) and the safety profile of catridecacog (recombinant factor XIII (rFXIII)) in children with congenital FXIII A-subunit deficiency. Young children (1 to less than 6 years old) with congenital FXIII deficiency are evaluated.

NCT ID: NCT01228669 Completed - Healthy Clinical Trials

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

Explorer 1
Start date: October 25, 2010
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia A or B

NCT ID: NCT01220141 Completed - Clinical trials for Congenital Bleeding Disorder

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Start date: November 2010
Phase: N/A
Study type: Observational

This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).

NCT ID: NCT01205724 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

pathfinder™1
Start date: September 2010
Phase: Phase 1
Study type: Interventional

This trial is conducted globally. The aim of this clinical trial is to investigate the safety and pharmacokinetics (the determination of the concentration of the administered medication in blood over time) of NNC 0129-0000-1003 in previously treated subjects with severe haemophilia A.